# EDGAR Filing Document

**Accession Number:** 0001567264
**File Stem:** 0000000000-23-000706
**Filing Date:** 2023-1
**Character Count:** 5846
**Document Hash:** 6b0722288f2878ca044b9bbfddf7b194
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000706.hdr.sgml**: 20230728

**ACCESSION NUMBER**: 0000000000-23-000706

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230123

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTENSITY THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001567264
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 461488089
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 61 WILTON ROAD, 3RD FLOOR
- **CITY:** WESTPORT
- **STATE:** CT
- **ZIP:** 06880
- **BUSINESS PHONE:** 203-221-7381

**MAIL ADDRESS:**
- **STREET 1:** 61 WILTON ROAD, 3RD FLOOR
- **CITY:** WESTPORT
- **STATE:** CT
- **ZIP:** 06880

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Intensity Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20130117
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-21-048854

## Text-Extract

```

United States securities and exchange commission logo

                              January 23, 2023

       Lewis Bender
       Chief Executive Officer
       Intensity Therapeutics, Inc.
       61 Wilton Road, 3rd Floor
       Westport, CT 06880

                                                        Re: Intensity
Therapeutics, Inc.
                                                            Amendment No. 11 to
Registration Statement on Form S-1
                                                            Filed January 13,
2023
                                                            File No. 333-260565

       Dear Lewis Bender:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 11 to Form S-1 filed January 13, 2023

       Our Strengths, page 54

   1.                                                   Please expand your
discussion to describe the grade 3 and 4 adverse events in your IT-01
                                                        study and quantify the
number of each type of event, as well as all other serious adverse
                                                        events. Make similar
revisions throughout your document, including in the discussion of
                                                        your results, to
identify all serious adverse events and quantify the number of each type of
                                                        event.
              You may contact Sasha Parikh at 202-551-3627 or Al Pavot at
202-551-3738 if you have
       questions regarding comments on the financial statements and related
matters. Please contact
       Jane Park at 202-551-7439 or Suzanne Hayes at 202-551-3675 with any
other questions.
 Lewis Bender
Intensity Therapeutics, Inc.
January 23, 2023
Page 2

                                            Sincerely,
FirstName LastNameLewis Bender
                                            Division of Corporation Finance
Comapany NameIntensity Therapeutics, Inc.
                                            Office of Life Sciences
January 23, 2023 Page 2
cc:       Daniel Woodard, Esq.
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 23, 2023

Lewis Bender  
Chief Executive Officer  
Intensity Therapeutics, Inc.  
61 Wilton Road, 3rd Floor  
Westport, CT 06880

**Re: Intensity Therapeutics, Inc.**

**Amendment No. 11 to Registration Statement on Form S-1**

**Filed January 13, 2023**

**File No. 333-260565**

Dear Lewis Bender:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Amendment No. 11 to Form S-1 filed January 13, 2023

Our Strengths, page 54

1. Please expand your discussion to describe the grade 3 and 4 adverse events in your IT-01 study and quantify the number of each type of event, as well as all other serious adverse events. Make similar revisions throughout your document, including in the discussion of your results, to identify all serious adverse events and quantify the number of each type of event.

You may contact Sasha Parikh at 202-551-3627 or Al Pavot at 202-551-3738 if you have questions regarding comments on the financial statements and related matters. Please contact Jane Park at 202-551-7439 or Suzanne Hayes at 202-551-3675 with any other questions.

Lewis Bender
Intensity Therapeutics, Inc.
January 23, 2023
Page 2

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Daniel Woodard, Esq.